StockData
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. (NRXP) stock

NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$2.15−0.40 (-15.69%)

Close on Nov 20, 2026Market cap $93.09MP/E –Yield –

NRX Pharmaceuticals gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

NRX Pharmaceuticals's gross profit for the twelve months ending Jun 30, 2026 was $1.58M. For fiscal 2025 it was $720.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$720.00K–
FY2024Dec 31, 2024$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$426.00K–
Q1 FY2026Mar 31, 2026$437.00K–
Q4 FY2025Dec 31, 2025$575.00K–
Q3 FY2025Sep 30, 2025$145.00K–
Q2 FY2025Jun 30, 2025$0–
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$0–
Q3 FY2024Sep 30, 2024$0–

More NRX Pharmaceuticals figures

See a number that looks wrong?